Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$75B
P/E ratio
18×
Revenue (FY25)
$14.3B
Net income (FY25)
$4.5B
Diluted EPS
$41.48
Dupixent profit share
$5.2B
Eylea franchise
$7.9B
Rev. growth
+1%
In plain English
Regeneron is an antibody-discovery powerhouse: its proprietary platforms (VelociSuite) breed fully-human antibodies that became blockbusters — the eye drug Eylea (now defended by next-gen Eylea HD against a wave of 2026 biosimilars) and, with long-time partner Sanofi, the immunology giant Dupixent. It discovers and grows its own biologic medicines in bioreactors in New York and Ireland, and is pushing into oncology, genetic medicines and radiopharmaceuticals through partnerships and bolt-on acquisitions.
In simple terms
What Regeneron really sells
Regeneron is an antibody-discovery powerhouse: its proprietary platforms (VelociSuite) breed fully-human antibodies that became blockbusters — the eye drug Eylea (now defended by next-gen Eylea HD against a wave of 2026 biosimilars) and, with long-time partner Sanofi, the immunology giant Dupixent. It discovers and grows its own biologic medicines in bioreactors in New York and Ireland, and is pushing into oncology, genetic medicines and radiopharmaceuticals through partnerships and bolt-on acquisitions.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.